Adeona is developing reaZin, a product candidate for the dietary management of Alzheimer’s disease and mild cognitive impairment, as a prescription medical food.
reaZin, formerly named Zinthionein, is a proprietary, gastroretentive, sustained release, once-daily oral tablet formulated from zinc (150 mg) and cysteine (100 mg), an amino acid with potent anti-oxidant properties.
reaZin demonstrated increased serum zinc and decreased serum free copper when administered in patients.
In addition, the average cognitive function of the placebo group declined over 6 months in comparison to patients managed with reaZin.
Adeona CEO James Kuo said executing this agreement for the manufacturing of the product candidate, reaZin, is an important step for commercialization.